



enhancing & facilitating HIV research

SESSION VI

Wrap-up


- Moderator: Veronica Miller



KEY POINTS

enhancing & facilitating HIV research

- Research on CVD risk in HIV populations has potential to contribute significantly to the field overall
- More and more reliance on epidemiologic and observational studies
 - For clinical guidelines
 - For drug labels
 - **Make *best* use of epidemiological studies**
- Much to learn regarding underlying pathophysiology
- Design and implement focused (pilot) intervention trials
- Review and update clinical guidelines and drug labels as appropriate and information becomes available





THINGS TO DO

- Research role of HIV infection per se in CVD risk framework
- Dissect the contribution of HIV, antiretroviral treatment, traditional and non-traditional risk factors
- Learn how to best treat (prevention; prevention) risk and events
- Work towards better standardization and/or harmonization across observational studies
- Encourage data sharing and independent review and/or evaluation of datasets



FOLLOW-UP AND NEXT STEPS

- Website posting
 - Webcast of June 23 public meeting
 - Roundtable materials
 - Summary of relevant studies



FEEDBACK

- Email us with
 - Comments, questions, critiques
 - Ideas for additional roundtables in this topic area
 - We plan to keep a webportal open with relevant new studies/data
 - ◉ Email us your publications!